Werewolf Therapeutics, Inc. (HOWL) Earnings
Werewolf Therapeutics, Inc.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Jul 31, 2026
From the latest earnings 8-K
Revenue • FY2025
$0
As reported
Diluted EPS • FY2025
-$1.33
▲ 18.4%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from HOWL's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $0 | -$60.82M | — | -$1.33 | -$60.29M | — | — |
| FY2024 | $0 | -$70.52M | — | -$1.63 | -$56.44M | — | — |
| FY2023 | $0 | -$37.37M | — | -$1.05 | -$33.38M | — | — |
| FY2022 | $0 | -$53.81M | — | -$1.86 | -$44.21M | — | — |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Jul 31, 2026 | 8-K (2.02) | 0001785530-26-000018EDGAR |
| May 7, 2026 | 8-K (2.02) | 0001785530-26-000011EDGAR |
| Mar 27, 2026 | 8-K (2.02) | 0001785530-26-000005EDGAR |
| Nov 4, 2025 | 8-K (2.02) | 0001785530-25-000030EDGAR |
| Aug 14, 2025 | 8-K (2.02) | 0001785530-25-000020EDGAR |
| May 8, 2025 | 8-K (2.02) | 0001785530-25-000013EDGAR |
| Mar 11, 2025 | 8-K (2.02) | 0001785530-25-000006EDGAR |
| Nov 7, 2024 | 8-K (2.02) | 0001785530-24-000033EDGAR |
Never miss a HOWL filing.
Get an email when HOWL files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 9, 2026Source: SEC EDGAR.